Tagged with Gene therapy

Cell & Gene Therapy Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as younger people with disabilities, has recently announced it will be increasing reimbursement rates and expanding coverage for cell and gene therapy treatments, good news for cancer patients and pharma companies Gilead…

USA PhRMA’s Anne McDonald Pritchett PhD highlights the remarkable development of cell and gene therapies in recent years and the three ways in which the US healthcare system can better accommodate them: creating manufacturing systems that take treatment timelines into account, a health system that values treatments based on patient outcomes,…

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) highlights why cell and gene therapies seem finally braced for mainstream adoption as well as the significant barriers that still need to be overcome for large patient numbers to access these innovative and often costly treatments.   Today, [ATMPs] finally seem to…

Opinion Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies for attracting and retaining talent in these rapidly emerging fields.   In a young industry experiencing rapid growth, talent demand far outweighs supply Cell & Gene Therapy; “It’s no longer something people read about…

Opinion Frost & Sullivan’s Senior Research Analyst, Aarti Chitale looks at the sizeable impact that precision medicine, especially regenerative medicine, is already having on the global therapeutic landscape, and how the Asia-Pacific region is positioning itself at the forefront of this trend.   Providing the right treatment/ right drug at the…

USA Christopher P. Molineaux of Life Sciences Pennsylvania outlines the Keystone State’s rich lineage of pharmaceutical innovation, how the association is building inter-state and international connections, and why Philadelphia is justified in branding itself as the ‘Cellicon Valley’.   We are at the epicentre of cell and gene therapy, what we…

Taiwan Dr Jan-Mou Lee, founder of FullHope Biomedical, shares his story of how he came to establish his company after a realization about the loss of impact that occurs when critical research is never transferred outside of the laboratory. Dr Lee goes on to explain his Full Hope’s revolutionary platform that…

Sweden Anders Blanck, director general of LIF, Sweden’s association representing the research-based pharmaceutical industry, breaks down the ins and outs of the country’s regionalized healthcare system and the drivers of the Swedish pharmaceutical market. He then delves into the reforms Sweden needs to undertake for its healthcare system to adapt to…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities.   Background Cell and gene therapies hold the promise of bringing significant clinical benefits to patients by directly targeting the underlying cause of disease. With tremendous…

Taiwan Rita Huang, dean of the Office of Research and Development and the director of the TMU Research Center for Cell Therapy and Regeneration Medicine highlights the center’s unique capabilities and its innovative research projects within the emerging space of stem cell treatments. She goes on to give her insights on…

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…

France Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities in the market.   Thanks to their versatility, oncolytic viruses can, therefore, be very potent. Our Invir.IO™ platform will be…